Zymeworks (ZYME)
(Real Time Quote from BATS)
$13.05 USD
0.00 (0.00%)
Updated Sep 20, 2024 12:26 PM ET
3-Hold of 5 3
F Value A Growth C Momentum C VGM
Brokerage Reports
0 items in cart
Zymeworks Inc. [ZYME]
Reports for Purchase
Showing records 1 - 20 ( 60 total )
Company: Zymeworks Inc.
Industry: Medical - Biomedical and Genetics
2Q24 Financials Reported; Catalysts Upcoming; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Zymeworks Inc.
Industry: Medical - Biomedical and Genetics
ZW171 FDA Clinical Clearance; Zanidatamab China Review Starts; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Zymeworks Inc.
Industry: Medical - Biomedical and Genetics
ZW171 FDA Clinical Clearance; Zanidatamab China Review Starts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Zymeworks Inc.
Industry: Medical - Biomedical and Genetics
OS Results for HERIZON-BTC-01 Presented; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Zymeworks Inc.
Industry: Medical - Biomedical and Genetics
Company: Zymeworks Inc.
Industry: Medical - Biomedical and Genetics
ZW191 May Hit FRa More Broadly vs. Elahere; AACR Data; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Zymeworks Inc.
Industry: Medical - Biomedical and Genetics
Company: Zymeworks Inc.
Industry: Medical - Biomedical and Genetics
HERIZON-GEA-01 Data in Late 2024; 2023 Financials; Raising PT to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Zymeworks Inc.
Industry: Medical - Biomedical and Genetics
Topline HERIZON-GEA-01 Data Expected in 2024; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Zymeworks Inc.
Industry: Medical - Biomedical and Genetics
Company: Zymeworks Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for ZYME 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: Zymeworks Inc.
Industry: Medical - Biomedical and Genetics
Multiple Datasets Presented; 3Q23 Financial Results; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Zymeworks Inc.
Industry: Medical - Biomedical and Genetics
2Q23 Financial Results Reported; Lengthy Cash Runway; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Zymeworks Inc.
Industry: Medical - Biomedical and Genetics
Company: Zymeworks Inc.
Industry: Medical - Biomedical and Genetics
HERIZON-BTC-01 Data Presented at ASCO; 1Q23 Financials; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Zymeworks Inc.
Industry: Medical - Biomedical and Genetics
Financial Results; Bispecific Collaboration Concluded; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Zymeworks Inc.
Industry: Medical - Biomedical and Genetics
Zanidatamab + Chemo Phase 2 1L GEA Results Presented; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Zymeworks Inc.
Industry: Medical - Biomedical and Genetics
Jazz Exercises Zanidatamab Option; Lowering PT to $8
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R